Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | Director | January 22, 2020 | January 24, 2020 |
| Biomea Fusion, Inc.BMEA · Entity 6606 | Director | June 10, 2026 | June 12, 2026 |
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director | June 22, 2026 | June 24, 2026 |
| Eidos Therapeutics, Inc.EIDX · Entity 143355 | Director | May 27, 2020 | May 29, 2020 |
| Invitae CorpNVTA · Entity 95935 | Director | April 27, 2023 | May 01, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biohaven Pharmaceutical Holding Co Ltd.
Report date January 22, 2020 · Filed January 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 2,021 |
Reported balance
After 2020-01-22 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-01-22 · Exercise / conversion · Acquired 771 · Balance 2,021 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 3,271 |
Reported balance
After 2020-01-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-01-22 · Exercise / conversion · Acquired 1,250 · Balance 3,271 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 2,771 |
Reported balance
After 2020-01-22 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-01-22 · Sale · Disposed 500 · Balance 2,771 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.38 - $55.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 2,271 |
Reported balance
After 2020-01-22 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2020-01-22 · Sale · Disposed 500 · Balance 2,271 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.39 - $56.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 1,600 |
Reported balance
After 2020-01-22 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2020-01-22 · Sale · Disposed 671 · Balance 1,600 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.41 - $57.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 1,400 |
Reported balance
After 2020-01-22 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2020-01-22 · Sale · Disposed 200 · Balance 1,400 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.70 - $58.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 1,250 |
Reported balance
After 2020-01-22 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2020-01-22 · Sale · Disposed 150 · Balance 1,250 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.70 - $59.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.54 · Expires 2027-09-04 | IndirectBy Spouse | 2,500 |
Reported balance
After 2020-01-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-01-22 · Exercise / conversion · Disposed 1,250 · Balance 2,500 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F7: The option, representing a right to purchase a total of 5,000 shares was granted on September 5, 2017, vesting in four equal installments on September 5, 2018, 2019, 2020 and 2021, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 1,250 shares on November 22, 2019. F8: This employee stock option is held by the Reporting Person's spouse. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.42 · Expires 2028-11-19 | IndirectBy Spouse | 22,500 |
Reported balance
After 2020-01-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-01-22 · Exercise / conversion · Disposed 771 · Balance 22,500 F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F9: The option, representing a right to purchase a total of 30,000 shares was granted on November 20, 2018, vesting in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 6,729 shares on November 20, 2019. F8: This employee stock option is held by the Reporting Person's spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.38 - $55.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.39 - $56.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.41 - $57.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.70 - $58.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.70 - $59.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F7: The option, representing a right to purchase a total of 5,000 shares was granted on September 5, 2017, vesting in four equal installments on September 5, 2018, 2019, 2020 and 2021, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 1,250 shares on November 22, 2019.
F8: This employee stock option is held by the Reporting Person's spouse.
F9: The option, representing a right to purchase a total of 30,000 shares was granted on November 20, 2018, vesting in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 6,729 shares on November 20, 2019.
Biomea Fusion, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2036-06-09 | Direct | 196,299 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 196,299 · Balance 196,299 F1: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
BridgeBio Pharma, Inc.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,579 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 3,990 · Balance 10,579 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.92 · Expires 2036-06-21 | Direct | 5,277 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 5,277 · Balance 5,277 F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
Eidos Therapeutics, Inc.
Report date May 27, 2020 · Filed May 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.51 · Expires 2030-05-27 | Direct | 21,528 |
Reported balance
After 2020-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-27 · Grant · Acquired 21,528 · Balance 21,528 F1: The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on May 26, 2021, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on May 26, 2021, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended).
Invitae Corp
Report date April 27, 2023 · Filed May 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,322 |
Reported balance
After 2023-04-27 transaction · row 1
1 source rowRow 1 · 2023-04-27 · Grant · Acquired 70,422 · Balance 125,322 F1: Shares issuable upon settlement of a restricted stock unit award that vests in full on May 15, 2024, subject to continued service with the Issuer through the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2033-04-27 | Direct | 28,901 |
Reported balance
After 2023-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-04-27 · Grant · Acquired 28,901 · Balance 28,901 F2: Option vests in twelve equal monthly installments starting from April 27, 2023, subject to continued service with the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares issuable upon settlement of a restricted stock unit award that vests in full on May 15, 2024, subject to continued service with the Issuer through the vesting date.
F2: Option vests in twelve equal monthly installments starting from April 27, 2023, subject to continued service with the Issuer through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2020 Filed Jan 24, 2020 18:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 1,250 | $37.54 | $46,925.00 |
DisclosureSEC source: 0001562180-20-000570 · primarydocument.xml · nonDerivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 18:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 771 | $32.42 | $24,995.82 |
DisclosureSEC source: 0001562180-20-000570 · primarydocument.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 19:46 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0001562180-20-000347 · primarydocument.xml · derivative · entry 4 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 30,000 shares Expires 2026-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, representing a right to purchase a total of 30,000 shares was granted on December 15, 2016, vested in four equal installments on December 15, 2016, 2017, 2018 and 2019, subject to the optionholder's continuous service with the Issuer at each vesting date. Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 19:46 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 30,000 | $56.39 | $1,691,700.00 |
DisclosureSEC source: 0001562180-20-000347 · primarydocument.xml · nonDerivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 09, 2020 Filed Jan 10, 2020 19:46 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 30,000 | $9.29 | $278,700.00 |
DisclosureSEC source: 0001562180-20-000347 · primarydocument.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 19:46 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionRestricted Share Unit Award · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-000347 · primarydocument.xml · derivative · entry 6 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,750 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F3 · derivative.exercise_date: The reporting person was granted 5,000 restricted share units on January 8, 2020, vesting in four equal installments on January 8, 2020, 2021, 2022 and 2023 subject to the reporting person's continued service with the issuer at each vesting date. F4 · derivative.expiration_date: Not applicable. F5 · ownership.nature: This restricted stock unit is held by the reporting person's spouse as an employee of the issuer. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 19:46 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantRestricted Share Unit Award · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-000347 · primarydocument.xml · derivative · entry 5 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of Biohaven Pharmaceutical Holding Co Ltd. F3 · derivative.exercise_date: The reporting person was granted 5,000 restricted share units on January 8, 2020, vesting in four equal installments on January 8, 2020, 2021, 2022 and 2023 subject to the reporting person's continued service with the issuer at each vesting date. F4 · derivative.expiration_date: Not applicable. F5 · ownership.nature: This restricted stock unit is held by the reporting person's spouse as an employee of the issuer. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 19:46 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 1,250 | $55.91 | $69,887.50 |
DisclosureSEC source: 0001562180-20-000347 · primarydocument.xml · nonDerivative · entry 3 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:40 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $52.13 | $0.00 |
DisclosureSEC source: 0001689813-19-000130 · wf-form4_157689598816947.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2029-12-18 F1 · derivative.exercise_date: The option became exercisable with respect to 3,000 of the shares underlying the option on the grant date (December 18, 2019), and the remaining 9,000 shares underlying the option vest in three equal installments on December 18, 2020, 2021 and 2022, subject to the optionholder's continuous service with the issuer as of each applicable vesting date. F2 · ownership.nature: This stock option is held by the reporting person's spouse as an employee of the issuer. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:39 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,537 | $0.00 Strike: $20.79 | $0.00 |
DisclosureSEC source: 0001689813-19-000118 · wf-form4_157672315313106.xml · derivative · entry 3 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 15,218 Underlying: Common Shares · 3,537 shares Expires 2027-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 30,436 shares was granted on December 7, 2017, vesting in four equal installments on December 7, 2018, 2019, 2020 and 2021, subject to the optionholder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 7,609 shares on February 4, 2019 and 4,072 shares on December 9, 2019. F4 · ownership.nature: This employee stock option is held by the Reporting Person's spouse. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:39 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 3,537 | $55.13 | $194,984.55 |
DisclosureSEC source: 0001689813-19-000118 · wf-form4_157672315313106.xml · nonDerivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 - $55.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 21:39 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 3,537 | $20.79 | $73,534.23 |
DisclosureSEC source: 0001689813-19-000118 · wf-form4_157672315313106.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:03 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 82,878 | $0.00 Strike: $37.45 | $0.00 |
DisclosureSEC source: 0000899243-19-029352 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,878 Underlying: Common Stock · 82,878 shares Expires 2029-12-11 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after December 12, 2019, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,072 | $0.00 Strike: $20.79 | $0.00 |
DisclosureSEC source: 0001689813-19-000116 · wf-form4_157611858026350.xml · derivative · entry 3 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 18,755 Underlying: Common Shares · 4,072 shares Expires 2027-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 30,436 shares was granted on December 7, 2017, vesting in four equal installments on December 7, 2018, 2019, 2020 and 2021, subject to the optionholder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 7,609 shares on February 4, 2019. F4 · ownership.nature: This employee stock option is held by the Reporting Person's spouse. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 4,072 | $55.11 | $224,410.77 |
DisclosureSEC source: 0001689813-19-000116 · wf-form4_157611858026350.xml · nonDerivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 - $55.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:43 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 4,072 | $20.79 | $84,656.88 |
DisclosureSEC source: 0001689813-19-000116 · wf-form4_157611858026350.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 4,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. Read SEC document |
| November 22, 2019 Filed Nov 22, 2019 21:37 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,250 | $0.00 Strike: $37.54 | $0.00 |
DisclosureSEC source: 0001689813-19-000097 · wf-form4_157447662358923.xml · derivative · entry 6 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,750 Underlying: Common Shares · 1,250 shares Expires 2027-09-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 5,000 shares was granted on September 5, 2017, vesting in four equal installments on September 5, 2018, 2019, 2020 and 2021, subject to the Reporting Person's spouse continuous service with the issuer at each vesting date. Read SEC document |
| November 22, 2019 Filed Nov 22, 2019 21:37 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 1,250 | $55.24 | $69,050.00 |
DisclosureSEC source: 0001689813-19-000097 · wf-form4_157447662358923.xml · nonDerivative · entry 4 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. Read SEC document |
| November 22, 2019 Filed Nov 22, 2019 21:37 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 1,250 | $37.54 | $46,925.00 |
DisclosureSEC source: 0001689813-19-000097 · wf-form4_157447662358923.xml · nonDerivative · entry 3 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:37 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,729 | $0.00 Strike: $32.42 | $0.00 |
DisclosureSEC source: 0001689813-19-000097 · wf-form4_157447662358923.xml · derivative · entry 5 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 23,271 Underlying: Common Shares · 6,729 shares Expires 2028-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 30,000 shares was granted on November 20, 2018, vesting in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the Reporting Person's spouse continuous service with the issuer at each vesting date. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:37 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 6,729 | $52.20 | $351,234.29 |
DisclosureSEC source: 0001689813-19-000097 · wf-form4_157447662358923.xml · nonDerivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.31 - $53.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:37 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 6,729 | $32.42 | $218,154.18 |
DisclosureSEC source: 0001689813-19-000097 · wf-form4_157447662358923.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 6,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 16:34 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $25.51 | $0.00 |
DisclosureSEC source: 0001689813-19-000063 · wf-form4_156840679456814.xml · derivative · entry 3 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 20,000 Underlying: Common Shares · 10,000 shares Expires 2027-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 40,000 shares was granted on August 4, 2017, vesting in four equal installments on July 5, 2018, 2019, 2020 and 2021, subject to the optionholder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 10,000 shares on February 4, 2019. F3 · ownership.nature: This employee stock option is held by the Reporting Person's spouse. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 16:34 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 10,000 | $45.00 | $450,000.00 |
DisclosureSEC source: 0001689813-19-000063 · wf-form4_156840679456814.xml · nonDerivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 16:34 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 10,000 | $25.51 | $255,100.00 |
DisclosureSEC source: 0001689813-19-000063 · wf-form4_156840679456814.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. Read SEC document |
| July 03, 2019 Filed Jul 8, 2019 21:29 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | PurchaseCommon Stock | 882,353 | $29.90 | $26,382,795.88 |
DisclosureSEC source: 0000899243-19-019339 · doc4.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 24,575,501 F1 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 21:27 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantStock Option (right to buy) · Derivative | 21,528 | $0.00 Strike: $30.87 | $0.00 |
DisclosureSEC source: 0000899243-19-016956 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,528 Underlying: Common Stock · 21,528 shares Expires 2029-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on June 12, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended). Read SEC document |
| May 24, 2019 Filed May 29, 2019 19:13 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | PurchaseCommon Stock | 1,103,848 | $25.93 | $28,622,778.64 |
DisclosureSEC source: 0000899243-19-015089 · doc4.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 23,693,148 F1 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| May 21, 2019 Filed May 23, 2019 18:34 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $61.76 | $0.00 |
DisclosureSEC source: 0001209191-19-032465 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2029-05-20 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 21, 2020 or (b) the date of the 2020 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| May 02, 2019 Filed May 6, 2019 23:09 UTC | Invitae Corp NVTA · Entity 95935 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.16 | $0.00 |
DisclosureSEC source: 0000899243-19-012319 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-02 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve equal monthly installments starting from May 2, 2019. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 18:21 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,609 | $0.00 Strike: $20.79 | $0.00 |
DisclosureSEC source: 0001209191-19-007869 · doc4.xml · derivative · entry 5 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 22,827 Underlying: Common Shares · 7,609 shares Expires 2027-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F5 · derivative.exercise_date: The shares underlying this option vest in four equal installments on December 7, 2018, 2019, 2020 and 2021, subject to the optionholder's continuous service with the Issuer at each vesting date. F4 · ownership.nature: This employee stock option is held by the Reporting Person's spouse. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 18:21 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $25.51 | $0.00 |
DisclosureSEC source: 0001209191-19-007869 · doc4.xml · derivative · entry 4 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 30,000 Underlying: Common Shares · 10,000 shares Expires 2027-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F3 · derivative.exercise_date: The shares underlying this option vest in four equal installments on July 5, 2018, 2019, 2020 and 2021, subject to the optionholder's continuous service with the Issuer at each vesting date. F4 · ownership.nature: This employee stock option is held by the Reporting Person's spouse. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 18:21 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 17,609 | $42.54 | $749,086.86 |
DisclosureSEC source: 0001209191-19-007869 · doc4.xml · nonDerivative · entry 3 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.54 - $42.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 18:21 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 7,609 | $20.79 | $158,191.11 |
DisclosureSEC source: 0001209191-19-007869 · doc4.xml · nonDerivative · entry 2 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 17,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 18:21 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Exercise / conversionCommon Shares | 10,000 | $25.51 | $255,100.00 |
DisclosureSEC source: 0001209191-19-007869 · doc4.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 00:17 UTC | Invitae Corp NVTA · Entity 95935 | SaleCommon Stock | 10,000 | $13.50 | $135,000.00 |
DisclosureSEC source: 0000899243-18-029769 · doc4.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 20, 2018 Filed Feb 14, 2019 16:30 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $32.42 | $0.00 |
DisclosureSEC source: 0001209191-19-010166 · doc5.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2028-11-19 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the reporting person's spouse continuous service with the issuer at each vesting date. F2 · ownership.nature: This stock option is held by the reporting person's spouse as an employee of the issuer. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 19:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantStock Option (right to buy) · Derivative | 43,056 | $0.00 Strike: $20.34 | $0.00 |
DisclosureSEC source: 0000899243-18-019331 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,056 Underlying: Common Stock · 43,056 shares Expires 2028-06-30 F1 · derivative.exercise_date: The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 43,056 stock options (the "Grant") on July 2, 2018. The Grant shall vest as follows: one-third of the stock options shall vest annually over a period of three (3) years following June 29, 2018 subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 00:39 UTC | Invitae Corp NVTA · Entity 95935 | GrantEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.08 | $0.00 |
DisclosureSEC source: 0000899243-18-018002 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-22 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve equal monthly installments starting from June 22, 2018. Read SEC document |
| May 01, 2018 Filed May 3, 2018 17:20 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $28.76 | $0.00 |
DisclosureSEC source: 0001209191-18-027716 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 1, 2019 or (b) the date of the 2019 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| December 07, 2017 Filed Dec 11, 2017 17:31 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,436 | $0.00 Strike: $20.79 | $0.00 |
DisclosureSEC source: 0001209191-17-065056 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 30,436 Underlying: Common Shares · 30,436 shares Expires 2027-12-06 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on December 7, 2018, 2019, 2020 and 2021, subject to the optionholder's continuous service with the issuer at each vesting date. F2 · ownership.nature: This employee stock option is held by the reporting person's spouse. Read SEC document |
| September 05, 2017 Filed Sep 12, 2017 18:24 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $37.54 | $0.00 |
DisclosureSEC source: 0001209191-17-052486 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 5,000 Underlying: Common Shares · 5,000 shares Expires 2027-09-04 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on September 5, 2018, 2019, 2020 and 2021, subject to the optionholder's continuous service with the issuer at each vesting date. F2 · ownership.nature: This employee stock option is held by the reporting person's spouse. Read SEC document |
| August 04, 2017 Filed Aug 8, 2017 16:03 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $25.51 | $0.00 |
DisclosureSEC source: 0001209191-17-048076 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2027-08-03 F1 · derivative.exercise_date: The shares underlying this option vest in four equal installments on July 5, 2018, 2019, 2020 and 2021, subject to the optionholder's continuous service with the issuer at each vesting date. F2 · ownership.nature: This employee stock option is held by the reporting person's spouse. Read SEC document |
| May 02, 2017 Filed May 4, 2017 20:09 UTC | Invitae Corp NVTA · Entity 95935 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0000899243-17-011813 · doc4.xml · derivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-02 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve equal monthly installments beginning on May 2, 2017. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 23:29 UTC | Invitae Corp NVTA · Entity 95935 | PurchaseCommon Stock | 10,000 | $6.28 | $62,834.00 |
DisclosureSEC source: 0000899243-16-034048 · doc4.xml · nonDerivative · entry 1 AGUIAR ERIC · CIK 0001262325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: Represents a weighted average purchase price for multiple transactions at prices ranging from $6.25 to $6.30, inclusive. Upon request by the Commission staff, the Company or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on November 18, 2016 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.